Spire Healthcare Group (LON:SPI) Sets New 1-Year High on Analyst Upgrade

Spire Healthcare Group plc (LON:SPI) reached a new 52-week high during mid-day trading on Thursday after Berenberg Bank raised their price target on the stock from GBX 286 to GBX 300. Berenberg Bank currently has a buy rating on the stock. Spire Healthcare Group traded as high as GBX 252.50 ($3.14) and last traded at GBX 248 ($3.09), with a volume of 3522562 shares. The stock had previously closed at GBX 238.50 ($2.97).

Separately, JPMorgan Chase & Co. reiterated an “overweight” rating and issued a GBX 295 ($3.67) target price on shares of Spire Healthcare Group in a research report on Monday, February 26th.

Spire Healthcare Group Stock Performance

The firm’s 50-day moving average is GBX 237.57 and its 200 day moving average is GBX 228.97. The stock has a market cap of £1.00 billion, a PE ratio of 3,542.86, a P/E/G ratio of 1.06 and a beta of 0.99. The company has a debt-to-equity ratio of 170.37, a quick ratio of 0.74 and a current ratio of 0.69.

Spire Healthcare Group Increases Dividend

The company also recently disclosed a dividend, which will be paid on Friday, June 21st. Shareholders of record on Thursday, May 23rd will be given a dividend of GBX 2.10 ($0.03) per share. The ex-dividend date is Thursday, May 23rd. This represents a yield of 0.89%. This is an increase from Spire Healthcare Group’s previous dividend of $0.50. Spire Healthcare Group’s dividend payout ratio is presently 4,285.71%.

About Spire Healthcare Group

Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening and surgery, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.